Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Actinium Pharmaceuticals, Inc. (ATNM)
USD0.92
+0.02 (+2.77%)
US AMEX Healthcare Biotechnology
Address
275 Madison Avenue 10016
New York City, NY, US
New York City, NY, US
CEO
Sandesh C. Seth
Website
actiniumpharma.com
IPO
2012-12-27
CIK 1388320 ISIN US00507W2061
Description
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.92
+0.02 (+2.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
181.9K
Beta
-0.05
Float Shares
30.84M
Free Float %
98.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.99% | +5.69% | +20.37% | +17.12% | +0.00% | -4.41% | -16.13% | -84.41% | -81.89% | -97.48% | -97.11% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
0.92
Low
4.00
+334.8%
Consensus
11.07
+1,103.4%
Median
4.95
+438.1%
High
24.26
+2,537.2%
DCF (Unlevered)
1.48
+61.1%
DCF (Levered)
1.48
+61.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 3 |
11.07
+1,103.4%
|
Quality scores
Altman Z-Score
-13.14
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+14.2% Q1'26: +64.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-40,260.0%
-
EBIT margin Biotechnology: +0.0%-40,274.4%
-
ROIC Biotechnology: -16.1%— Q1'26: +61.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.7% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.14M
est: 1.17M (-2.5%)
|
1.03M
est: 1.01M (+1.8%)
|
81.0K
est: 81.0K (+0.0%)
|
—
est: 42.5K (-100.0%)
|
90.0K
est: 90.0K (+0.0%)
|
12.91M
12.91M – 12.91M
+14,247.8% YoY
|
12.93M
12.93M – 12.93M
+0.1% YoY
|
28.25M
28.25M – 28.25M
+118.5% YoY
|
98.17M
98.17M – 98.17M
+247.5% YoY
|
182.25M
182.25M – 182.25M
+85.6% YoY
|
| EBITDA |
-24.25M
est: -234.7K (-10,230.9%)
|
-33.41M
est: -202.4K (-16,404.5%)
|
-51.13M
est: -16.2K (-315,536.8%)
|
-37.43M
est: -25.5K (-146,605.9%)
|
-35.43M
est: -54.0K (-65,503.7%)
|
-7.75M
-7.75M – -7.75M
-14,247.8% YoY
|
-7.76M
-7.76M – -7.76M
-0.1% YoY
|
-16.95M
-16.95M – -16.95M
-118.5% YoY
|
-58.90M
-58.90M – -58.90M
-247.5% YoY
|
-109.35M
-109.35M – -109.35M
-85.6% YoY
|
| EBIT |
-24.77M
est: -234.7K (-10,454.1%)
|
-34.10M
est: -202.4K (-16,749.9%)
|
-51.92M
est: -16.2K (-320,413.6%)
|
-38.24M
est: -25.5K (-149,784.4%)
|
-36.25M
est: -54.0K (-67,024.1%)
|
-7.75M
-7.75M – -7.75M
-14,247.8% YoY
|
-7.76M
-7.76M – -7.76M
-0.1% YoY
|
-16.95M
-16.95M – -16.95M
-118.5% YoY
|
-58.90M
-58.90M – -58.90M
-247.5% YoY
|
-109.35M
-109.35M – -109.35M
-85.6% YoY
|
| Net Income |
-24.77M
est: -34.78M (+28.8%)
|
-33.02M
est: -40.66M (+18.8%)
|
-48.82M
est: -51.44M (+5.1%)
|
-38.24M
est: -45.51M (+16.0%)
|
-33.89M
est: -33.54M (-1.0%)
|
-28.31M
-28.31M – -28.31M
+15.6% YoY
|
-27.45M
-27.45M – -27.45M
+3.0% YoY
|
-26.46M
-35.11M – 4.20M
+3.6% YoY
|
10.29M
10.29M – 10.29M
+138.9% YoY
|
45.39M
45.39M – 45.39M
+340.9% YoY
|
| SGA |
8.08M
est: 43.49M (-81.4%)
|
12.00M
est: 37.50M (-68.0%)
|
13.33M
est: 3.00M (+344.1%)
|
12.08M
est: 3.01M (+301.9%)
|
15.21M
est: 6.36M (+139.2%)
|
912.49M
912.49M – 912.49M
+14,247.8% YoY
|
913.46M
913.46M – 913.46M
+0.1% YoY
|
2.00B
2.00B – 2.00B
+118.5% YoY
|
6.94B
6.94B – 6.94B
+247.5% YoY
|
12.88B
12.88B – 12.88B
+85.6% YoY
|
| EPS |
-1.20
est: -1.16 (-3.7%)
|
-1.37
est: -1.35 (-1.3%)
|
-1.83
est: -1.71 (-7.0%)
|
-1.27
est: -1.41 (+10.2%)
|
-1.09
est: -1.08 (-1.4%)
|
-0.91
-0.91 – -0.91
+15.6% YoY
|
-0.88
-0.88 – -0.88
+3.0% YoY
|
-0.56
-1.13 – 0.13
+36.7% YoY
|
0.33
0.33 – 0.33
+159.3% YoY
|
1.46
1.46 – 1.46
+340.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.17M
OE per share TTM
-0.81
Owner's Yield
-66.14%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
544.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
252.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sabby Volatility Warrant Master Fund, Ltd. | 20.10M | 7.29% | — | 20.10M | — | 20.10M | CO | USA | 2020-05-01 | ↗ |
| 2 | (1) BlackRock, Inc. | 1.69M | 6.20% | 1.68M | — | 1.69M | — | HC | Delaware | 2024-01-29 | ↗ |
| 3 | The Vanguard Group | 1.63M | 5.21% | — | 48.6K | 1.57M | 57.5K | — | Pennsylvania | 2024-11-04 | ↗ |
| 4 | Michael Bigger | 1.31M | 6.00% | — | — | 162.1K | 1.16M | IN | USA | 2022-02-09 | ↗ |
| 5 | Perkins Capital Managment, Inc. | 1.31M | 6.10% | 1.08M | — | 1.31M | — | IA | — | 2021-02-11 | ↗ |
| 6 | District 2 Capital Fund LP | 513.1K | 2.30% | — | — | — | 513.1K | PN | USA | 2022-02-09 | ↗ |
| 7 | District 2 Capital LP | 513.1K | 2.30% | — | — | — | 513.1K | PN | USA | 2022-02-09 | ↗ |
| 8 | District 2 GP LLC | 513.1K | 2.30% | — | — | — | 513.1K | OO | USA | 2022-02-09 | ↗ |
| 9 | District 2 Holdings LLC | 513.1K | 2.30% | — | — | — | 513.1K | OO | USA | 2022-02-09 | ↗ |
| 10 | Eric Schlanger | 331.3K | 2.40% | — | — | 7.5K | 323.8K | IN | Delaware | 2020-08-12 | ↗ |
| 11 | Bigger Capital Fund GP, LLC | 323.2K | 1.50% | — | — | — | 323.2K | OO | USA | 2022-02-09 | ↗ |
| 12 | Bigger Capital Fund, LP | 323.2K | 1.50% | — | — | — | 323.2K | PN | USA | 2022-02-09 | ↗ |
| 13 | Patricia Winter | 107.8K | 1.00% | — | — | 107.8K | — | IN | USA | 2022-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-54 vs prev Q
New positions
0
Closed positions
52
Increased
0
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1.42M +36.5K (+2.6%) | 1.93M -282.7K (-12.8%) | 4.56% +0.117 pp | 0.00% +0.000 pp | USD7.51 -81.9% | 22 qtrs — |
| 2 | ACADIAN ASSET MANAGEMENT LLC | 606.3K +116.8K (+23.8%) | 823.0K +41.0K (+5.2%) | 1.94% +0.374 pp | 0.00% +0.000 pp | USD1.73 -21.4% | 6 qtrs — |
| 3 | MILLENNIUM MANAGEMENT LLC | 601.6K -23.1K (-3.7%) | 818.2K -181.3K (-18.1%) | 1.93% -0.074 pp | 0.00% 0.000 pp | USD1.40 -2.9% | 8 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 390.8K +102.2K (+35.4%) | 531.5K +69.7K (+15.1%) | 1.25% +0.328 pp | 0.00% +0.000 pp | USD1.55 -12.3% | 7 qtrs — |
| 5 | BLACKROCK, INC. | 366.9K +3.4K (+0.9%) | 499.0K -82.6K (-14.2%) | 1.18% +0.011 pp | 0.00% +0.000 pp | USD1.86 -26.9% | 6 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 329.0K +575.0 (+0.2%) | 447.6K -78.1K (-14.9%) | 1.05% +0.002 pp | 0.00% +0.000 pp | USD7.38 -81.6% | 22 qtrs — |
| 7 | TWO SIGMA INVESTMENTS, LP | 209.7K -24.6K (-10.5%) | 285.2K -89.7K (-23.9%) | 0.67% -0.079 pp | 0.00% 0.000 pp | USD1.56 -12.8% | 3 qtrs — |
| 8 | GAGNON SECURITIES LLC | 201.8K -24.5K (-10.8%) | 274.5K -87.6K (-24.2%) | 0.65% -0.078 pp | 0.06% -0.017 pp | USD1.61 -15.5% | 4 qtrs — |
| 9 | TWO SIGMA ADVISERS, LP | 196.1K -300.0 (-0.2%) | 266.7K -47.5K (-15.1%) | 0.63% -0.001 pp | 0.00% 0.000 pp | USD1.60 -15.0% | 2 qtrs — |
| 10 | STATE STREET CORP | 126.2K +— (+0.0%) | 171.7K -30.3K (-15.0%) | 0.40% +0.000 pp | 0.00% +0.000 pp | USD7.05 -80.7% | 19 qtrs — |
| 11 | GEN-WEALTH PARTNERS INC | 107.1K -2.3K (-2.1%) | 145.7K -29.3K (-16.7%) | 0.34% -0.007 pp | 0.05% -0.012 pp | USD1.60 -15.0% | 2 qtrs — |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 82.5K -23.0K (-21.8%) | 112.2K -56.5K (-33.5%) | 0.26% -0.074 pp | 0.00% +0.000 pp | USD2.83 -51.9% | 16 qtrs — |
| 13 | GOLDMAN SACHS GROUP INC | 70.4K +70.4K (+100.0%) | 95.7K +95.7K (+100.0%) | 0.23% +0.226 pp | 0.00% +0.000 pp | USD1.36 +0.0% | 14 qtrs — |
| 14 | SQUAREPOINT OPS LLC | 65.7K +65.7K (+100.0%) | 89.4K +89.4K (+100.0%) | 0.21% +0.211 pp | 0.00% +0.000 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 15 | BAILARD, INC. | 57.9K +57.9K (+100.0%) | 78.7K +78.7K (+100.0%) | 0.19% +0.186 pp | 0.00% +0.002 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 16 | NORTHERN TRUST CORP | 42.6K +6.7K (+18.7%) | 58.0K +518.0 (+0.9%) | 0.14% +0.022 pp | 0.00% +0.000 pp | USD6.24 -78.2% | 22 qtrs — |
| 17 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 40.0K +— (+0.0%) | 54.4K -9.6K (-15.0%) | 0.13% +0.000 pp | 0.00% 0.000 pp | USD7.86 -82.7% | 22 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 34.9K +— (+0.0%) | 47.5K -8.4K (-15.0%) | 0.11% +0.000 pp | 0.00% +0.000 pp | USD8.37 -83.8% | 18 qtrs — |
| 19 | VONTOBEL HOLDING LTD. | 30.0K +— (+0.0%) | 40.8K -7.2K (-15.0%) | 0.10% +0.000 pp | 0.00% +0.000 pp | USD1.32 +3.0% | 5 qtrs — |
| 20 | JANE STREET GROUP, LLC | 29.7K +29.7K (+100.0%) | 40.4K +40.4K (+100.0%) | 0.10% +0.095 pp | 0.00% +0.000 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 21 | AM INVESTMENT STRATEGIES LLC | 29.4K +29.4K (+100.0%) | 40.0K +40.0K (+100.0%) | 0.09% +0.094 pp | 0.01% +0.008 pp | USD1.36 +0.0% | 8 qtrs — |
| 22 | XTX TOPCO LTD | 26.0K +6.0K (+30.1%) | 35.3K +3.4K (+10.6%) | 0.08% +0.019 pp | 0.00% -0.001 pp | USD1.44 -5.6% | 6 qtrs — |
| 23 | CALLAN FAMILY OFFICE, LLC | 23.6K +— (+0.0%) | 32.1K -5.7K (-15.0%) | 0.08% +0.000 pp | 0.00% -0.001 pp | USD1.61 -15.5% | 4 qtrs — |
| 24 | MAYPORT, LLC | 22.0K +— (+0.0%) | 29.9K -5.3K (-15.0%) | 0.07% +0.000 pp | 0.01% -0.002 pp | USD1.60 -15.0% | 2 qtrs — |
| 25 | ADVISOR GROUP HOLDINGS, INC. | 20.3K +13.1K (+183.4%) | 27.6K +15.3K (+125.3%) | 0.07% +0.042 pp | 0.00% +0.000 pp | USD3.06 -55.6% | 22 qtrs — |
| 26 | NORTH STAR ASSET MANAGEMENT INC | 20.0K +— (+0.0%) | 27.2K -4.8K (-15.0%) | 0.06% +0.000 pp | 0.00% 0.000 pp | USD1.33 +2.3% | 5 qtrs — |
| 27 | WELLS FARGO & COMPANY/MN | 19.8K +— (+0.0%) | 26.9K -4.8K (-15.0%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD2.76 -50.7% | 22 qtrs — |
| 28 | MORGAN STANLEY | 19.1K +14.4K (+304.1%) | 25.9K +18.4K (+243.5%) | 0.06% +0.046 pp | 0.00% +0.000 pp | USD1.94 -29.9% | 22 qtrs — |
| 29 | QUBE RESEARCH & TECHNOLOGIES LTD | 18.8K -6.9K (-26.9%) | 25.6K -15.6K (-37.8%) | 0.06% -0.022 pp | 0.00% +0.000 pp | USD1.40 -2.9% | 3 qtrs — |
| 30 | CETERA INVESTMENT ADVISERS | 15.3K +768.0 (+5.3%) | 20.8K -2.4K (-10.5%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD1.59 -14.5% | 2 qtrs — |
| 31 | FMR LLC | 14.4K -6.7K (-31.9%) | 19.5K -14.2K (-42.1%) | 0.05% -0.022 pp | 0.00% +0.000 pp | USD2.20 -38.2% | 12 qtrs — |
| 32 | RUSSELL INVESTMENTS GROUP, LTD. | 13.3K +— (+0.0%) | 18.1K -3.2K (-15.0%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD1.85 -26.5% | 7 qtrs — |
| 33 | TWO SIGMA SECURITIES, LLC | 13.0K +13.0K (+100.0%) | 17.6K +17.6K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.002 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 34 | NINE MASTS CAPITAL LTD | 12.9K +12.9K (+100.0%) | 17.6K +17.6K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.003 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 35 | HRT FINANCIAL LP | 13.0K +13.0K (+100.0%) | 17.0K +17.0K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.000 pp | USD1.36 +0.0% | 3 qtrs — |
| 36 | INTREPID FINANCIAL PLANNING GROUP LLC | 10.5K -2.0K (-16.0%) | 14.3K -5.7K (-28.6%) | 0.03% -0.006 pp | 0.01% -0.002 pp | USD5.16 -73.6% | 15 qtrs — |
| 37 | POINT72 ASSET MANAGEMENT, L.P. | 10.3K +10.3K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 38 | SAVVY ADVISORS, INC. | 10.0K +10.0K (+100.0%) | 13.6K +13.6K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD1.36 +0.0% | 1 qtrs NEW |
| 39 | LEVEL FOUR ADVISORY SERVICES, LLC | 10.0K +— (+0.0%) | 13.6K -2.4K (-15.0%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD1.60 -15.0% | 2 qtrs — |
| 40 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 4.0K -500.0 (-11.1%) | 5.4K -1.8K (-24.4%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD1.60 -15.0% | 2 qtrs — |
| 41 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 2.2K +— (+0.0%) | 2.9K -520.0 (-15.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.86 -26.9% | 11 qtrs — |
| 42 | JPMORGAN CHASE & CO | 1.5K -68.0 (-4.4%) | 2.0K -467.0 (-18.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.93 -29.5% | 11 qtrs — |
| 43 | FEDERATED HERMES, INC. | 1.4K -522.0 (-27.1%) | 1.9K -1.2K (-38.1%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.66 -18.1% | 6 qtrs — |
| 44 | NISA INVESTMENT ADVISORS, LLC | 958.00 +— (+0.0%) | 1.3K -230.0 (-15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.57 -13.4% | 7 qtrs — |
| 45 | NATIONAL BANK OF CANADA /FI/ | 855.00 +— (+0.0%) | 1.2K -205.0 (-15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.01 -77.4% | 17 qtrs — |
| 46 | CWM, LLC | 620.00 -775.0 (-55.6%) | 1.0K -1.0K (-50.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD1.63 -16.6% | 17 qtrs — |
| 47 | SRS CAPITAL ADVISORS, INC. | 707.00 +673.0 (+1,979.4%) | 962.00 +908.0 (+1,681.5%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.37 -0.7% | 2 qtrs — |
| 48 | BANK OF AMERICA CORP /DE/ | 649.00 +1.0 (+0.2%) | 882.00 -155.0 (-14.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.02 -72.9% | 18 qtrs — |
| 49 | SBI SECURITIES CO., LTD. | 542.00 +— (+0.0%) | 737.00 -130.0 (-15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.26 +7.9% | 5 qtrs — |
| 50 | CITIGROUP INC | 431.00 -854.0 (-66.5%) | 586.00 -1.5K (-71.5%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD2.89 -52.9% | 14 qtrs — |
| 51 | JONES FINANCIAL COMPANIES LLLP | 351.00 +— (+0.0%) | 477.00 -88.0 (-15.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.43 -4.9% | 3 qtrs — |
| 52 | PITTENGER & ANDERSON INC | 341.00 +— (+0.0%) | 464.00 -82.0 (-15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.61 -15.5% | 4 qtrs — |
| 53 | INVESTORS RESEARCH CORP | 300.00 +— (+0.0%) | 408.00 -72.0 (-15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.57 -13.4% | 4 qtrs — |
| 54 | BNP PARIBAS ARBITRAGE, SNC | 237.00 +— (+0.0%) | 322.00 -57.0 (-15.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.26 +7.9% | 5 qtrs — |
| 55 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 107.00 +— (+0.0%) | 146.00 -25.0 (-14.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.68 -86.0% | 22 qtrs — |
| 56 | UBS GROUP AG | 96.00 -14.5K (-99.3%) | 131.00 -23.2K (-99.4%) | 0.00% -0.046 pp | 0.00% +0.000 pp | USD1.79 -24.0% | 14 qtrs — |
| 57 | EVERSOURCE WEALTH ADVISORS, LLC | 16.00 -70.0 (-81.4%) | 22.00 -116.0 (-84.1%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.38 -1.4% | 5 qtrs — |
| 58 | BARCLAYS PLC | 1.00 -42.9K (-100.0%) | 1.00 -80.7K (-100.0%) | 0.00% -0.138 pp | 0.00% +0.000 pp | USD1.00 +36.0% | 12 qtrs — |
| 59 | ADVISORY SERVICES NETWORK, LLC | — -2.5K (-100.0%) | — -3.9K (-100.0%) | 0.00% -0.008 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 60 | ROYAL BANK OF CANADA | — -5.7K (-100.0%) | — -9.0K (-100.0%) | 0.00% -0.018 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 61 | GROUPE LA FRANCAISE | — -316.0 (-100.0%) | — -436.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 62 | GROUP ONE TRADING, L.P. | — -547.0 (-100.0%) | — -875.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 63 | MARSHALL WACE, LLP | — -26.3K (-100.0%) | — -42.1K (-100.0%) | 0.00% -0.084 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 64 | TOWER RESEARCH CAPITAL LLC (TRC) | — -555.0 (-100.0%) | — -888.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 22 qtrs SOLD |
| 65 | TRUE WEALTH DESIGN, LLC | — -2.0 (-100.0%) | — -4.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 66 | CITADEL ADVISORS LLC | — -126.6K (-100.0%) | — -202.6K (-100.0%) | 0.00% -0.406 pp | 0.00% +0.000 pp | USD— | 18 qtrs SOLD |
| 67 | AQR CAPITAL MANAGEMENT LLC | — -16.8K (-100.0%) | — -26.9K (-100.0%) | 0.00% -0.054 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 99.3K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 388.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.5K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 6.7K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 497.42 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.15M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.5K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.4K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 554.71 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 61.12 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
120.9K
Cash buys
—
Cash sales
—
Net activity
-120,900
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-18 | SETH SANDESH | Director / Officer | F-InKind | D | Common Stock | 120,900 | 1.71 | 206.7K | 184,481 | D | ↗ |
| 2025-03-31 | Steinhart Richard I | Director | D-Return | D | Stock Option (Right to Buy) | 72,156 | 4.96 | 357.9K | 0 | D | ↗ |
| 2025-03-31 | Shetty Ajit | Director | D-Return | D | Stock Option (Right to Buy) | 70,311 | 5.00 | 351.6K | 0 | D | ↗ |
| 2025-03-31 | SETH SANDESH | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 16,666 | 59.70 | 995.0K | 0 | D | ↗ |
| 2025-03-31 | O'Loughlin Steve | Officer | D-Return | D | Stock Option (Right to Buy) | 8,833 | 23.49 | 207.5K | 0 | D | ↗ |
| 2025-03-31 | Nicholson, C. David | Director | D-Return | D | Stock Option (Right to Buy) | 70,311 | 5.00 | 351.6K | 0 | D | ↗ |
| 2025-03-31 | Chell Jeffrey W. | Director | D-Return | D | Stock Option (Right to Buy) | 2,500 | 23.49 | 58.7K | 0 | D | ↗ |
| 2025-03-31 | Almenoff June Sherie | Director | D-Return | D | Stock Option (Right to Buy) | 50,000 | 1.71 | 85.5K | 0 | D | ↗ |
| 2024-11-01 | Almenoff June Sherie | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.71 | 85.5K | 50,000 | D | ↗ |
| 2023-12-28 | Steinhart Richard I | Director | A-Award | A | Stock Option (Right to Buy) | 70,311 | 5.00 | 351.6K | 70,311 | — | ↗ |
| 2023-12-28 | Shetty Ajit | Director | A-Award | A | Stock Option (Right to Buy) | 70,311 | 5.00 | 351.6K | 70,311 | — | ↗ |
| 2023-12-28 | SETH SANDESH | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 984,367 | 5.00 | 4.92M | 984,367 | — | ↗ |
| 2023-12-28 | O'Loughlin Steve | Officer | A-Award | A | Stock Option (Right to Buy) | 253,123 | 5.00 | 1.27M | 253,123 | — | ↗ |
| 2023-12-28 | Nicholson, C. David | Director | A-Award | A | Stock Option (Right to Buy) | 70,311 | 5.00 | 351.6K | 70,311 | — | ↗ |
| 2023-12-28 | Chell Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 70,311 | 5.00 | 351.6K | 70,311 | — | ↗ |
| 2022-08-17 | SETH SANDESH | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 305,381 | — | ↗ |
| 2022-07-01 | Steinhart Richard I | Director | A-Award | A | Stock Option (Right to Buy) | 72,156 | 0.00 | — | 72,156 | — | ↗ |
| 2022-07-01 | Shetty Ajit | Director | A-Award | A | Stock Option (Right to Buy) | 72,156 | 0.00 | — | 72,156 | — | ↗ |
| 2022-07-01 | SETH SANDESH | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 827,366 | 4.96 | 4.10M | 827,366 | — | ↗ |
| 2022-07-01 | O'Loughlin Steve | Officer | A-Award | A | Stock Option (Right to Buy) | 256,438 | 0.00 | — | 256,348 | — | ↗ |
| 2022-07-01 | Nicholson, C. David | Director | A-Award | A | Stock Option (Right to Buy) | 72,156 | 4.96 | 357.9K | 72,156 | — | ↗ |
| 2022-07-01 | Chell Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 72,156 | 0.00 | — | 72,156 | — | ↗ |
| 2021-09-01 | Steinhart Richard I | Director | A-Award | A | Stock Option (Right to Buy) | 18,351 | 6.07 | 111.4K | 18,351 | — | ↗ |
| 2021-09-01 | Shetty Ajit | Director | A-Award | A | Stock Option (Right to Buy) | 18,351 | 6.07 | 111.4K | 18,351 | — | ↗ |
| 2021-09-01 | SETH SANDESH | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 310,182 | 6.07 | 1.88M | 310,182 | — | ↗ |
| 2021-09-01 | O'Loughlin Steve | Officer | A-Award | A | Stock Option (Right to Buy) | 107,463 | 6.07 | 652.3K | 107,463 | — | ↗ |
| 2021-09-01 | Nicholson, C. David | Director | A-Award | A | Stock Option (Right to Buy) | 18,351 | 6.07 | 111.4K | 18,351 | — | ↗ |
| 2021-09-01 | Chell Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 18,351 | 6.07 | 111.4K | 18,351 | — | ↗ |
| 2021-09-01 | Berger Mark Stanley | Officer | A-Award | A | Stock Option (Right to Buy) | 67,164 | 6.07 | 407.7K | 67,164 | — | ↗ |
| 2020-08-12 | Steinhart Richard I | Director | A-Award | A | Stock Option (Right to Buy) | 8,333 | 9.55 | 79.6K | 8,333 | — | ↗ |
| 2020-08-12 | Shetty Ajit | Director | A-Award | A | Stock Option (Right to Buy) | 8,333 | 9.55 | 79.6K | 8,333 | — | ↗ |
| 2020-08-12 | SETH SANDESH | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 139,062 | 9.55 | 1.33M | 139,062 | — | ↗ |
| 2020-08-12 | O'Loughlin Steve | Officer | A-Award | A | Stock Option (Right to Buy) | 59,066 | 9.55 | 564.1K | 59,066 | — | ↗ |
| 2020-08-12 | Nicholson, C. David | Director | A-Award | A | Stock Option (Right to Buy) | 8,333 | 9.55 | 79.6K | 8,333 | — | ↗ |
| 2020-08-12 | Ludwig Dale L. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 9.55 | 477.5K | 50,000 | — | ↗ |
| 2020-08-12 | Chell Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 8,333 | 9.55 | 79.6K | 8,333 | — | ↗ |
| 2020-08-12 | Berger Mark Stanley | Officer | A-Award | A | Stock Option (Right to Buy) | 46,667 | 9.55 | 445.7K | 46,667 | — | ↗ |
| 2019-07-12 | Steinhart Richard I | Director | A-Award | A | Options to purchase common stock | 250,000 | 0.23 | 58.0K | 250,000 | — | ↗ |
| 2019-07-12 | Shetty Ajit | Director | A-Award | A | Options to purchase common stock | 250,000 | 0.23 | 58.0K | 250,000 | — | ↗ |
| 2019-07-12 | SETH SANDESH | Director / Officer | A-Award | A | Options to purchase common stock | 1,500,000 | 0.23 | 348.0K | 1,500,000 | — | ↗ |
| 2019-07-12 | O'Loughlin Steve | Officer | A-Award | A | Options to purchase common stock | 400,000 | 0.23 | 92.8K | 400,000 | — | ↗ |
| 2019-07-12 | Nicholson, C. David | Director | A-Award | A | Options to purchase common stock | 250,000 | 0.23 | 58.0K | 250,000 | — | ↗ |
| 2019-07-12 | Ludwig Dale L. | Officer | A-Award | A | Options to purchase common stock | 400,000 | 0.23 | 92.8K | 400,000 | — | ↗ |
| 2019-07-12 | Kapur Anil | Officer | A-Award | A | Options to purchase common stock | 400,000 | 0.23 | 92.8K | 400,000 | — | ↗ |
| 2019-07-12 | Chell Jeffrey W. | Director | A-Award | A | Options to purchase common stock | 250,000 | 0.23 | 58.0K | 250,000 | — | ↗ |
| 2019-07-12 | Berger Mark Stanley | Officer | A-Award | A | Options to purchase common stock | 400,000 | 0.23 | 92.8K | 400,000 | — | ↗ |
| 2019-03-05 | Berger Mark Stanley | Officer | X-InTheMoney | A | Common Stock | 3,500 | 0.60 | 2.1K | 22,500 | — | ↗ |
| 2019-02-21 | SETH SANDESH | Director / Officer | X-InTheMoney | A | Common Stock | 8,125 | 0.60 | 4.9K | 161,458 | — | ↗ |
| 2018-12-10 | SETH SANDESH | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.44 | 4.4K | 153,333 | — | ↗ |
| 2018-12-10 | O'Loughlin Steve | Officer | P-Purchase | A | Common Stock | 10,000 | 0.44 | 4.4K | 35,500 | — | ↗ |
| 2018-11-19 | Ludwig Dale L. | Officer | P-Purchase | A | Common Stock | 10,000 | 0.45 | 4.5K | 10,000 | — | ↗ |
| 2018-07-17 | SETH SANDESH | Director / Officer | P-Purchase | A | Common stock | 10,000 | 0.79 | 7.9K | 143,333 | — | ↗ |
| 2018-07-13 | Steinhart Richard I | Director | A-Award | A | Options to purchase common stock | 75,000 | 0.78 | 58.7K | 75,000 | — | ↗ |
| 2018-07-13 | Shetty Ajit | Director | A-Award | A | Options to purchase common stock | 75,000 | 0.78 | 58.7K | 75,000 | — | ↗ |
| 2018-07-13 | SETH SANDESH | Director / Officer | A-Award | A | Options to purchase common stock | 1,000,000 | 0.78 | 782.9K | 1,000,000 | — | ↗ |
| 2018-07-13 | Ray Nitya G. | Officer | A-Award | A | Options to purchase common stock | 75,000 | 0.78 | 58.7K | 75,000 | — | ↗ |
| 2018-07-13 | O'Loughlin Steve | Officer | A-Award | A | Options to purchase common stock | 265,000 | 0.78 | 207.5K | 265,000 | — | ↗ |
| 2018-07-13 | Nicholson, C. David | Director | A-Award | A | Options to purchase common stock | 75,000 | 0.78 | 58.7K | 75,000 | — | ↗ |
| 2018-07-13 | Chell Jeffrey W. | Director | A-Award | A | Options to purchase common stock | 75,000 | 0.78 | 58.7K | 75,000 | — | ↗ |
| 2018-07-13 | Berger Mark Stanley | Officer | A-Award | A | Options to purchase common stock | 250,000 | 0.78 | 195.7K | 250,000 | — | ↗ |
| 2018-06-15 | O'Loughlin Steve | Officer | P-Purchase | A | Common Stock | 12,000 | 0.50 | 6.0K | 25,500 | — | ↗ |
| 2018-04-27 | Chell Jeffrey W. | Director | — | D | Options to purchase common stock | 75,000 | 0.35 | 26.3K | 0 | — | ↗ |
| 2018-04-19 | SETH SANDESH | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.38 | 1.9K | 133,333 | — | ↗ |
| 2018-03-06 | Steinhart Richard I | Director | J-Other | A | Common Stock | 7,000 | 0.50 | 3.5K | 9,500 | — | ↗ |
| 2018-03-06 | SETH SANDESH | Director / Officer | J-Other | A | Series A Warrants | 13,125 | 0.60 | 7.9K | 13,125 | — | ↗ |
| 2018-03-06 | Ray Nitya G. | Officer | J-Other | A | Series B Warrants | 7,500 | 0.70 | 5.3K | 7,500 | — | ↗ |
| 2018-03-06 | O'Loughlin Steve | Officer | J-Other | A | Series A Warrants | 2,500 | 0.60 | 1.5K | 2,500 | — | ↗ |
| 2018-03-06 | Berger Mark Stanley | Officer | J-Other | A | Common Stock | 14,000 | 0.50 | 7.0K | 19,000 | — | ↗ |
| 2018-02-28 | Shetty Ajit | Director | P-Purchase | A | Common stock | 22,730 | 0.43 | 9.8K | 22,730 | — | ↗ |
| 2018-02-06 | Kapur Anil | Officer | — | D | Options to purchase common stock | 475,000 | 0.64 | 304.0K | 0 | — | ↗ |
| 2018-01-08 | Ludwig Dale L. | Officer | — | D | Options to purchase common stock | 200,000 | 0.72 | 144.0K | 0 | — | ↗ |
| 2017-08-02 | SETH SANDESH | Director / Officer | P-Purchase | A | Common Stock | 33,333 | 0.75 | 25.0K | 75,833 | — | ↗ |
| 2017-08-02 | Ray Nitya G. | Officer | P-Purchase | A | Common Stock | 10,000 | 0.75 | 7.5K | 10,000 | — | ↗ |
| 2017-06-15 | SETH SANDESH | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 1.16 | 5.8K | 42,500 | — | ↗ |
| 2017-06-15 | Ray Nitya G. | Officer | — | D | Options to purchase common stock | 250,000 | 1.15 | 287.5K | 0 | — | ↗ |
| 2017-06-15 | O'Loughlin Steve | Officer | P-Purchase | A | Common stock | 3,500 | 1.17 | 4.1K | 3,500 | — | ↗ |
| 2017-06-15 | Berger Mark Stanley | Officer | P-Purchase | A | Common stock | 5,000 | 1.11 | 5.6K | 5,000 | — | ↗ |
| 2017-03-28 | Shetty Ajit | Director | — | D | Options to purchase common stock | 75,000 | 1.58 | 118.5K | 0 | — | ↗ |
| 2017-03-14 | TRAVERSA SERGIO | Director | A-Award | A | Options to purchase common stock | 75,000 | 1.39 | 104.3K | 75,000 | — | ↗ |
| 2017-03-14 | Steinhart Richard I | Director | A-Award | A | Options to purchase common stock | 75,000 | 1.39 | 104.3K | 75,000 | — | ↗ |
| 2017-03-14 | SETH SANDESH | Director / Officer | J-Other | A | Warrant to purchase common stock | 99,619 | 0.78 | 77.7K | 100 | — | ↗ |
| 2017-03-14 | O'Loughlin Steve | Officer | — | D | Options to purchase common stock | 100,000 | 1.39 | 139.0K | 0 | — | ↗ |
| 2017-03-14 | Nicholson, C. David | Director | A-Award | A | Options to purchase common stock | 75,000 | 1.39 | 104.3K | 75,000 | — | ↗ |
| 2017-03-14 | DAVE KAUSHIK J | Director / Officer | A-Award | A | Options to purchase common stock | 250,000 | 1.39 | 347.5K | 250,000 | — | ↗ |
| 2017-03-14 | CICIC DRAGAN | Officer | A-Award | A | Options to purchase common stock | 75,000 | 1.39 | 104.3K | 75,000 | — | ↗ |
| 2017-01-17 | Berger Mark Stanley | Officer | — | D | Options to purchase common stock | 325,000 | 1.04 | 338.0K | 0 | — | ↗ |
| 2016-12-30 | SETH SANDESH | Director / Officer | P-Purchase | A | Common stock | 5,000 | 0.88 | 4.4K | 35,000 | — | ↗ |
| 2016-12-12 | SETH SANDESH | Director / Officer | P-Purchase | A | Common stock | 5,000 | 0.98 | 4.9K | 30,000 | — | ↗ |
| 2016-08-31 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 25,188 | 1.80 | 45.3K | 4,821,226 | — | ↗ |
| 2016-08-30 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 23,500 | 1.80 | 42.3K | 4,878,988 | — | ↗ |
| 2016-08-29 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 12,500 | 1.71 | 21.4K | 4,914,988 | — | ↗ |
| 2016-08-26 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 12,002 | 1.71 | 20.5K | 4,927,488 | — | ↗ |
| 2016-08-16 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 400 | 1.73 | 690.00 | 4,952,488 | — | ↗ |
| 2016-08-15 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 4,439 | 1.72 | 7.6K | 4,957,517 | — | ↗ |
| 2016-07-12 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 3,000 | 1.80 | 5.4K | 4,962,056 | — | ↗ |
| 2016-07-11 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 800 | 1.80 | 1.4K | 4,965,056 | — | ↗ |
| 2016-07-08 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 21,190 | 1.80 | 38.1K | 4,965,856 | — | ↗ |
| 2016-07-06 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 10,500 | 1.80 | 18.9K | 4,987,046 | — | ↗ |
| 2016-07-05 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 6,000 | 1.82 | 10.9K | 5,001,886 | — | ↗ |
| 2016-07-01 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 5,900 | 1.86 | 11.0K | 5,013,936 | — | ↗ |
| 2016-06-30 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 15,200 | 1.80 | 27.4K | 5,140,786 | — | ↗ |
| 2016-06-15 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 33,619 | 1.90 | 63.9K | 5,155,986 | — | ↗ |
| 2016-06-02 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 11,000 | 2.00 | 22.0K | 5,196,395 | — | ↗ |
| 2016-06-01 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 200 | 2.18 | 436.00 | 5,207,395 | — | ↗ |
| 2016-05-31 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 300 | 1.94 | 580.50 | 5,312,008 | — | ↗ |
| 2016-05-26 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 27,168 | 1.92 | 52.2K | 5,389,745 | — | ↗ |
| 2016-05-25 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 26,000 | 1.90 | 49.4K | 5,427,313 | — | ↗ |
| 2016-04-26 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 4,000 | 1.95 | 7.8K | 5,455,813 | — | ↗ |
| 2016-04-25 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 1,200 | 2.02 | 2.4K | 5,466,498 | — | ↗ |
| 2016-04-22 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 3,692 | 2.08 | 7.7K | 5,478,298 | — | ↗ |
| 2016-04-21 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 3,700 | 2.05 | 7.6K | 5,505,890 | — | ↗ |
| 2016-04-20 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 10,473 | 2.04 | 21.4K | 5,518,890 | — | ↗ |
| 2016-04-19 | Memorial Sloan-Kettering Cancer Center | 10% Owner | S-Sale | D | Common Stock | 2,133 | 2.07 | 4.4K | 5,555,807 | — | ↗ |
| 2016-04-18 | SETH SANDESH | Director | P-Purchase | A | Common Stock | 5,000 | 1.98 | 9.9K | 23,500 | — | ↗ |
| 2016-04-15 | TRAVERSA SERGIO | Director | P-Purchase | A | Common Stock | 1,000 | 2.02 | 2.0K | 3,000 | — | ↗ |
| 2016-04-15 | Steinhart Richard I | Director | A-Award | A | Options to purchase common stock | 75,000 | 1.99 | 149.3K | 75,000 | — | ↗ |
| 2016-04-15 | SETH SANDESH | Director | P-Purchase | A | Common Stock | 1,500 | 2.01 | 3.0K | 18,500 | — | ↗ |
| 2016-04-15 | Nicholson, C. David | Director | A-Award | A | Options to purchase common stock | 75,000 | 1.99 | 149.3K | 75,000 | — | ↗ |
| 2016-04-15 | DAVE KAUSHIK J | Director / Officer | A-Award | A | Options to purchase common stock | 400,000 | 1.99 | 796.0K | 400,000 | — | ↗ |
| 2016-04-15 | CICIC DRAGAN | Officer | A-Award | A | Options to purchase common stock | 50,000 | 1.99 | 99.5K | 50,000 | — | ↗ |
| 2016-04-14 | TRAVERSA SERGIO | Director | P-Purchase | A | Common Stock | 2,000 | 2.02 | 4.0K | 2,000 | — | ↗ |
| 2016-04-14 | Steinhart Richard I | Director | P-Purchase | A | Common Stock | 2,500 | 2.01 | 5.0K | 2,500 | — | ↗ |
| 2016-04-14 | SETH SANDESH | Director | P-Purchase | A | Common Stock | 5,000 | 2.00 | 10.0K | 15,000 | — | ↗ |
| 2016-04-14 | O'Loughlin Steve | Officer | — | D | Options to purchase common stock | 50,000 | 1.99 | 99.5K | 0 | — | ↗ |
| 2016-04-14 | Nicholson, C. David | Director | P-Purchase | A | Common Stock | 5,000 | 2.00 | 10.0K | 15,000 | — | ↗ |
| 2016-04-14 | DAVE KAUSHIK J | Director / Officer | P-Purchase | A | Common Stock | 8,000 | 2.02 | 16.2K | 86,500 | — | ↗ |
| 2015-10-01 | O'Loughlin Steve | Officer | — | D | Options to purchase common stock | 100,000 | 1.79 | 179.0K | 0 | — | ↗ |
| 2015-05-07 | DAVE KAUSHIK J | Director / Officer | A-Award | A | Options to purchase common stock | 63,063 | 2.52 | 158.9K | 63,063 | — | ↗ |
| 2015-05-07 | CICIC DRAGAN | Officer | D-Return | D | Common stock | 2,380 | 2.52 | 6.0K | 560 | — | ↗ |
| 2015-05-06 | Memorial Sloan-Kettering Cancer Center | 10% Owner | J-Other | A | Common Stock | 5,702,387 | 0.00 | — | 5,702,387 | — | ↗ |
| 2015-02-18 | TRAVERSA SERGIO | Director | A-Award | A | Options to purchase common stock | 25,000 | 3.58 | 89.5K | 25,000 | — | ↗ |
| 2015-02-18 | Steinhart Richard I | Director | A-Award | A | Options to purchase common stock | 25,000 | 3.58 | 89.5K | 25,000 | — | ↗ |
| 2015-02-18 | DAVE KAUSHIK J | Director / Officer | A-Award | A | Options to purchase common stock | 150,000 | 3.58 | 537.0K | 150,000 | — | ↗ |
| 2015-02-18 | CICIC DRAGAN | Officer | A-Award | A | Options to purchase common stock | 35,000 | 3.58 | 125.3K | 35,000 | — | ↗ |
| 2014-09-23 | SETH SANDESH | Director / Officer | A-Award | A | Options | 150,000 | 3.58 | 537.0K | 150,000 | — | ↗ |
| 2014-02-21 | CICIC DRAGAN | Officer | A-Award | A | Options to purchase common stock | 31,500 | 5.55 | 174.8K | 31,500 | — | ↗ |
| 2013-12-16 | Steinhart Richard I | Director | A-Award | A | Options to purchase common stock | 49,950 | 6.70 | 334.7K | 49,950 | — | ↗ |
| 2013-12-16 | DAVE KAUSHIK J | Director / Officer | A-Award | A | Options to purchase common stock | 675,000 | 6.70 | 4.52M | 675,000 | — | ↗ |
| 2013-11-08 | Steinhart Richard I | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-09-16 | DAVE KAUSHIK J | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2013-08-22 | Memorial Sloan-Kettering Cancer Center | 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 5,702,387 | — | ↗ |
| 2013-08-08 | TRAVERSA SERGIO | Director / Officer | A-Award | A | Options to purchase common stock | 20,000 | 3.60 | 72.0K | 4,995 | — | ↗ |
| 2013-08-08 | SETH SANDESH | Director | A-Award | A | Restricted Stock | 10,000 | 3.60 | 36.0K | 0 | — | ↗ |
| 2013-07-25 | SETH SANDESH | Director | J-Other | A | Common Stock Purchase Warrant | 721,068 | 0.01 | 7.2K | 178,350 | — | ↗ |
| 2013-05-15 | MAZANET ROSEMARY | Director | P-Purchase | A | Common Stock | 100 | 3.95 | 395.00 | 100 | — | ↗ |
| 2012-12-28 | Talley John V. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-12-28 | TRAVERSA SERGIO | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-12-28 | SETH SANDESH | Director | — | D | Options to purchase common stock | 49,950 | 1.50 | 74.9K | 0 | — | ↗ |
| 2012-12-28 | Nicholson, C. David | Director | — | D | Options to purchase common stock | 49,950 | 1.50 | 74.9K | 0 | — | ↗ |
| 2012-12-28 | Memorial Sloan-Kettering Cancer Center | 10% Owner | — | I | Common Stock, par value $0.01 per share | 0 | 0.00 | — | 5,702,387 | — | ↗ |
| 2012-12-28 | MAZANET ROSEMARY | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-12-28 | GUAGENTI ENZA | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-12-28 | CICIC DRAGAN | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-01-31 | SETH SANDESH | Director | — | D | Common Stock Purchase Warrant | 64,747 | 0.78 | 50.8K | 0 | — | ↗ |
| 2007-02-07 | Button Diane S | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 20,000,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-11.7K
Shares Outstanding
31.37M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Sandesh Seth Chairman and Chief Executive Officer | 733.2K | 440.0K | — | — | — | — | 1.17M | 0.00% | ↗ |
| 2 | 2024 | Steve O’Loughlin Chief Financial Officer | 436.8K | 145.0K | — | — | — | — | 581.8K | 0.00% | ↗ |
| 3 | 2023 | Sandesh Seth Chairman and Chief Executive Officer | 705.0K | 500.0K | — | 3.50M | — | — | 4.71M | 74.39% | ↗ |
| 4 | 2023 | Steve O’Loughlin Chief Financial Officer | 420.0K | 170.0K | — | 900.0K | — | — | 1.49M | 60.40% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sandesh C. Seth | CEO, Principal Financial Officer & Chairman | 1M | male |
| Jenny Hsieh | Chief Strategy Officer | — | female |
| Lynn Bodarky | Chief Business Officer | — | female |
| Madhuri Vusirikala | Vice President of Clinical Development BMT & Cellular Therapy | — | — |
| Paul Diamond | Vice President of Patent & Legal Counsel | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATNM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
